Oral Aleniglipron Reduced Weight at 36 Weeks - Poll - MDSpire

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

What Changes Under 2025 ASE Diastolic Function Criteria?

Researchers evaluated 300,828 adult transthoracic echocardiograms using the 2016 and 2025 American Society of Echocardiography diastolic function guidelines; 87,724 met criteria for analysis.

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.